Literature DB >> 18371590

Influence of chronic renal failure on the heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT.

Andrea De Lorenzo1, Ronaldo S L Lima.   

Abstract

BACKGROUND: Dipyridamole promotes a reduction in blood pressure and an increase in heart rate (HR), considered the normal hemodynamic response to the drug. Data suggest that patients with chronic renal failure (CRF) have an attenuation of this hemodynamic response. This study sought to evaluate the HR response to dipyridamole and its determinants in patients with or without CRF undergoing gated myocardial perfusion single photon emission computed tomography. METHODS AND
RESULTS: Consecutive patients (n = 355, 9.6% with CRF) undergoing rest/dipyridamole myocardial perfusion single photon emission computed tomography were evaluated. The HR response to dipyridamole was considered to be reduced if the HR ratio (maximal HR/rest HR) was 1.20 or less. A logistic regression analysis determined independent predictors of a blunted HR response. A reduced HR response was found in 84.4% of patients with CRF and 40.6% of those without CRF (P < .0001). In patients without CRF the independent predictors of abnormal HR response were hypertension, rest and differential perfusion scores, and left ventricular ejection fraction. In contrast, in CRF patients there was no significant association of any of the studied variables with abnormal HR response.
CONCLUSIONS: An abnormal HR response to dipyridamole is frequently found in patients with CRF. Different mechanisms may account for abnormal HR response in patients with or without CRF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371590     DOI: 10.1016/j.nuclcard.2007.10.006

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  23 in total

1.  Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms.

Authors:  Rohit Bhatheja; Gary S Francis; Claire E Pothier; Michael S Lauer
Journal:  Am J Cardiol       Date:  2005-05-15       Impact factor: 2.778

Review 2.  Dipyridamole.

Authors:  G A FitzGerald
Journal:  N Engl J Med       Date:  1987-05-14       Impact factor: 91.245

3.  Study of the activity of lymphocyte adenosine deaminase in chronic renal failure.

Authors:  K Melissinos; A Delidou; S Grammenou; P Markopoulos
Journal:  Clin Chim Acta       Date:  1983-11-30       Impact factor: 3.786

Review 4.  Coronary artery disease in uremia: Etiology, diagnosis, and therapy.

Authors:  D J Goldsmith; A Covic
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

5.  Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study.

Authors:  Aiden Abidov; Rory Hachamovitch; Sean W Hayes; Chee Keong Ng; Ishac Cohen; John D Friedman; Guido Germano; Daniel S Berman
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

6.  Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs.

Authors:  T Sharir; B Rabinowitz; S Livschitz; I Moalem; J Baron; E Kaplinsky; P Chouraqui
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

7.  Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise.

Authors:  H G Stratmann; B R Tamesis; L T Younis; M D Wittry; D D Miller
Journal:  Am J Cardiol       Date:  1994-04-01       Impact factor: 2.778

8.  Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging.

Authors:  Raymond Taillefer; Alan W Ahlberg; Yasmin Masood; C Michael White; Isabella Lamargese; Jeffrey F Mather; Carol C McGill; Gary V Heller
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

9.  Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease.

Authors:  R C Hendel; J J Layden; J A Leppo
Journal:  J Am Coll Cardiol       Date:  1990-01       Impact factor: 24.094

10.  Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure.

Authors:  T H Marwick; D R Steinmuller; D A Underwood; R E Hobbs; R T Go; C Swift; W E Braun
Journal:  Transplantation       Date:  1990-01       Impact factor: 4.939

View more
  2 in total

1.  Prognostic value of vasodilator response using rubidium-82 positron emission tomography myocardial perfusion imaging in patients with coronary artery disease.

Authors:  Punitha Arasaratnam; Masoud Sadreddini; Yeung Yam; Vinay Kansal; Sharmila Dorbala; Marcelo F Di Carli; Rob S Beanlands; Michael E Merhige; Brent A Williams; Emir Veledar; James K Min; Li Chen; Terrence D Ruddy; Guido Germano; Daniel S Berman; Leslee J Shaw; Benjamin J W Chow
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-27       Impact factor: 9.236

2.  Blunted heart rate response as a predictor of cardiac death in patients undergoing vasodilator stress technetium-99m sestamibi gated SPECT myocardial perfusion imaging.

Authors:  Shishir Mathur; Anuj R Shah; Alan W Ahlberg; Deborah M Katten; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2010-05-19       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.